Novartis
1Q Revenues: $11.8 billion (+10%)
1Q Earnings: $2.7 billion (+25%)
Comments: Key growth drivers include Entresto with $1.9 billion in sales, up 34%, Cosentyx sales of $1.3 billion, up 23%, Kesimpta sales of $637 million, up 66%, Kisqali sales of $627 million, up 51%, Pluvicto sales of $310 million, up 47% and Leqvio sales of $151 million, up 136%. Promacta sales were down 5% to $520 million. Jakavi sales were up 15% to $478 million. Tafinlar+Mekinist sales were up 3% to $474 million. Xolair sales were $399 million, up 13%. Tasigna sales were down 15% to $395 million. Ilaris sales were $356 million, up 9%. Lucentis sales were down 25% to $314 million.